Abstract | BACKGROUND: METHODS: RESULTS: Clinical outcomes in 326 patients (96.7%) were analyzed and the 28-day uncorrected adequate clinical and parasitological response (ACPR) rate was 73.9%. The total PCR-corrected 28-day ACPR was 97.2%. The pfcrt 76T and pfmdr1 86Y population prevalence decreased from 49.3% and 11.0% at baseline (n = 337) to 38.8% and 0% in patients with recurrent infection (n = 85); p = 0.001), respectively. CONCLUSION:
|
Authors | Hamma Maiga, Anastasia Grivoyannis, Issaka Sagara, Karim Traore, Oumar B Traore, Youssouf Tolo, Aliou Traore, Amadou Bamadio, Zoumana I Traore, Kassim Sanogo, Ogobara K Doumbo, Christopher V Plowe, Abdoulaye A Djimde |
Journal | International journal of molecular sciences
(Int J Mol Sci)
Vol. 22
Issue 11
(Jun 03 2021)
ISSN: 1422-0067 [Electronic] Switzerland |
PMID | 34205228
(Publication Type: Journal Article)
|
Chemical References |
- Artemether, Lumefantrine Drug Combination
- Artemisinins
- Mdr1 protein, Plasmodium falciparum
- Membrane Transport Proteins
- Multidrug Resistance-Associated Proteins
- PfCRT protein, Plasmodium falciparum
- Protozoan Proteins
- Chloroquine
- artemisinin
|
Topics |
- Alleles
- Artemether, Lumefantrine Drug Combination
(administration & dosage, adverse effects)
- Artemisinins
(administration & dosage, adverse effects)
- Child
- Child, Preschool
- Chloroquine
(administration & dosage, adverse effects)
- Drug Resistance
(genetics)
- Female
- Humans
- Malaria, Falciparum
(drug therapy, genetics, parasitology, pathology)
- Male
- Membrane Transport Proteins
(genetics)
- Multidrug Resistance-Associated Proteins
(genetics)
- Plasmodium falciparum
(drug effects, pathogenicity)
- Protozoan Proteins
(genetics)
|